Supracervical hysterectomy in patients with advanced epithelial ovarian cancer

Michael R. Milam, Anil K. Sood, Sara King, Roland L. Bassett, Karen H. Lu, Brian Slomovitz, Robert L. Coleman, Pedro T. Ramirez

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

OBJECTIVE: To assess whether supracervical hysterectomy (SCH) is a reasonable alternative to total abdominal hysterectomy in patients with advanced ovarian cancer. METHODS: We reviewed the records of patients with advanced ovarian cancer who underwent a SCH at one institution between 1993 and 2004 and a similar cohort who underwent total abdominal hysterectomy (TAH) at the same institution during the same period. Patients without complete surgical staging done at the institution were excluded. Independent-sample t tests, Fisher exact test, and log rank tests were used for statistical analysis. RESULTS: The study included 47 patients who underwent SCH (mean age, 59.6 years) and 190 who underwent TAH. There were no significant differences between the two groups in age (P=.51), preoperative CA 125 level (P=.55), or receipt of taxane-based and platinum-based chemotherapy (P=.84). Although limited by sample size, there were no significant differences between the two groups in rates of intraoperative complications (4 of 47 in the SCH group, or 8.5%, compared with 7 of 190 in the TAH group, or 3.7%; P=.24), vaginal or cervical recurrence (5 of 47 in the SCH group, or 10.6%, compared with 22 of 190 in the TAH group, or 11.6%; P=1.00), or in progression-free survival (SCH of 1.01 years compared with TAH of 1.19 years; P=.64) or overall survival (SCH of 3.28 years compared with TAH of 3.36 years; P=.12). CONCLUSION: Supracervical hysterectomy may be a reasonable alternative to TAH in patients with advanced ovarian cancer.

Original languageEnglish (US)
Pages (from-to)641-646
Number of pages6
JournalObstetrics and Gynecology
Volume109
Issue number3
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Hysterectomy
Ovarian Neoplasms
Ovarian epithelial cancer
Intraoperative Complications
Platinum
Sample Size
Disease-Free Survival

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Milam, M. R., Sood, A. K., King, S., Bassett, R. L., Lu, K. H., Slomovitz, B., ... Ramirez, P. T. (2007). Supracervical hysterectomy in patients with advanced epithelial ovarian cancer. Obstetrics and Gynecology, 109(3), 641-646. https://doi.org/10.1097/01.AOG.0000257117.78230.0f

Supracervical hysterectomy in patients with advanced epithelial ovarian cancer. / Milam, Michael R.; Sood, Anil K.; King, Sara; Bassett, Roland L.; Lu, Karen H.; Slomovitz, Brian; Coleman, Robert L.; Ramirez, Pedro T.

In: Obstetrics and Gynecology, Vol. 109, No. 3, 03.2007, p. 641-646.

Research output: Contribution to journalArticle

Milam, MR, Sood, AK, King, S, Bassett, RL, Lu, KH, Slomovitz, B, Coleman, RL & Ramirez, PT 2007, 'Supracervical hysterectomy in patients with advanced epithelial ovarian cancer', Obstetrics and Gynecology, vol. 109, no. 3, pp. 641-646. https://doi.org/10.1097/01.AOG.0000257117.78230.0f
Milam, Michael R. ; Sood, Anil K. ; King, Sara ; Bassett, Roland L. ; Lu, Karen H. ; Slomovitz, Brian ; Coleman, Robert L. ; Ramirez, Pedro T. / Supracervical hysterectomy in patients with advanced epithelial ovarian cancer. In: Obstetrics and Gynecology. 2007 ; Vol. 109, No. 3. pp. 641-646.
@article{9543063aa9f242c2aa826528773cb3e7,
title = "Supracervical hysterectomy in patients with advanced epithelial ovarian cancer",
abstract = "OBJECTIVE: To assess whether supracervical hysterectomy (SCH) is a reasonable alternative to total abdominal hysterectomy in patients with advanced ovarian cancer. METHODS: We reviewed the records of patients with advanced ovarian cancer who underwent a SCH at one institution between 1993 and 2004 and a similar cohort who underwent total abdominal hysterectomy (TAH) at the same institution during the same period. Patients without complete surgical staging done at the institution were excluded. Independent-sample t tests, Fisher exact test, and log rank tests were used for statistical analysis. RESULTS: The study included 47 patients who underwent SCH (mean age, 59.6 years) and 190 who underwent TAH. There were no significant differences between the two groups in age (P=.51), preoperative CA 125 level (P=.55), or receipt of taxane-based and platinum-based chemotherapy (P=.84). Although limited by sample size, there were no significant differences between the two groups in rates of intraoperative complications (4 of 47 in the SCH group, or 8.5{\%}, compared with 7 of 190 in the TAH group, or 3.7{\%}; P=.24), vaginal or cervical recurrence (5 of 47 in the SCH group, or 10.6{\%}, compared with 22 of 190 in the TAH group, or 11.6{\%}; P=1.00), or in progression-free survival (SCH of 1.01 years compared with TAH of 1.19 years; P=.64) or overall survival (SCH of 3.28 years compared with TAH of 3.36 years; P=.12). CONCLUSION: Supracervical hysterectomy may be a reasonable alternative to TAH in patients with advanced ovarian cancer.",
author = "Milam, {Michael R.} and Sood, {Anil K.} and Sara King and Bassett, {Roland L.} and Lu, {Karen H.} and Brian Slomovitz and Coleman, {Robert L.} and Ramirez, {Pedro T.}",
year = "2007",
month = "3",
doi = "10.1097/01.AOG.0000257117.78230.0f",
language = "English (US)",
volume = "109",
pages = "641--646",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Supracervical hysterectomy in patients with advanced epithelial ovarian cancer

AU - Milam, Michael R.

AU - Sood, Anil K.

AU - King, Sara

AU - Bassett, Roland L.

AU - Lu, Karen H.

AU - Slomovitz, Brian

AU - Coleman, Robert L.

AU - Ramirez, Pedro T.

PY - 2007/3

Y1 - 2007/3

N2 - OBJECTIVE: To assess whether supracervical hysterectomy (SCH) is a reasonable alternative to total abdominal hysterectomy in patients with advanced ovarian cancer. METHODS: We reviewed the records of patients with advanced ovarian cancer who underwent a SCH at one institution between 1993 and 2004 and a similar cohort who underwent total abdominal hysterectomy (TAH) at the same institution during the same period. Patients without complete surgical staging done at the institution were excluded. Independent-sample t tests, Fisher exact test, and log rank tests were used for statistical analysis. RESULTS: The study included 47 patients who underwent SCH (mean age, 59.6 years) and 190 who underwent TAH. There were no significant differences between the two groups in age (P=.51), preoperative CA 125 level (P=.55), or receipt of taxane-based and platinum-based chemotherapy (P=.84). Although limited by sample size, there were no significant differences between the two groups in rates of intraoperative complications (4 of 47 in the SCH group, or 8.5%, compared with 7 of 190 in the TAH group, or 3.7%; P=.24), vaginal or cervical recurrence (5 of 47 in the SCH group, or 10.6%, compared with 22 of 190 in the TAH group, or 11.6%; P=1.00), or in progression-free survival (SCH of 1.01 years compared with TAH of 1.19 years; P=.64) or overall survival (SCH of 3.28 years compared with TAH of 3.36 years; P=.12). CONCLUSION: Supracervical hysterectomy may be a reasonable alternative to TAH in patients with advanced ovarian cancer.

AB - OBJECTIVE: To assess whether supracervical hysterectomy (SCH) is a reasonable alternative to total abdominal hysterectomy in patients with advanced ovarian cancer. METHODS: We reviewed the records of patients with advanced ovarian cancer who underwent a SCH at one institution between 1993 and 2004 and a similar cohort who underwent total abdominal hysterectomy (TAH) at the same institution during the same period. Patients without complete surgical staging done at the institution were excluded. Independent-sample t tests, Fisher exact test, and log rank tests were used for statistical analysis. RESULTS: The study included 47 patients who underwent SCH (mean age, 59.6 years) and 190 who underwent TAH. There were no significant differences between the two groups in age (P=.51), preoperative CA 125 level (P=.55), or receipt of taxane-based and platinum-based chemotherapy (P=.84). Although limited by sample size, there were no significant differences between the two groups in rates of intraoperative complications (4 of 47 in the SCH group, or 8.5%, compared with 7 of 190 in the TAH group, or 3.7%; P=.24), vaginal or cervical recurrence (5 of 47 in the SCH group, or 10.6%, compared with 22 of 190 in the TAH group, or 11.6%; P=1.00), or in progression-free survival (SCH of 1.01 years compared with TAH of 1.19 years; P=.64) or overall survival (SCH of 3.28 years compared with TAH of 3.36 years; P=.12). CONCLUSION: Supracervical hysterectomy may be a reasonable alternative to TAH in patients with advanced ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=33847387040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847387040&partnerID=8YFLogxK

U2 - 10.1097/01.AOG.0000257117.78230.0f

DO - 10.1097/01.AOG.0000257117.78230.0f

M3 - Article

C2 - 17329515

AN - SCOPUS:33847387040

VL - 109

SP - 641

EP - 646

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 3

ER -